Antimicrobials
Remdesivir

Remdesivir

Restricted

N/A
N/A
$$$$

Spectrum of Activity

Dosing

General Information

Administration

  • Infuse over 30-120 minutes

Preparation

  • Injection solution: allow vial to warm to room temperature, remove equal volume from the NS bag, then further dilute in 250mL of NS Lyophilized powder:
  • Reconstitute with 19mL of SWFI and shake vial for 30 seconds (final concentration 5mg/mL)
  • Allow to settle 2-3 minutes
  • Withdraw and discard required volume from NS bag (40mL for 200mg dose, 20mL for 100mg dose)
  • Further dilute in NS 250mL bag

Diluent

  • NS

Treatment of COVID-19 disease in adults and pediatric patients 12 y.o. and older weighing at least 40kg requiring hospitilization

Tier Four

  • ID physician and/or Intensivist consult and signed patient consent required for use
  • Prior to 1st dose: eGFR, hepatic laboratory, and prothrombin time
  • During therapy: as clinically appropriate
  • Increased Risk of Transaminase Elevations
  • Skin rash
  • Nausea
  • Prolonged prothrombin time
  • Seizure (<2%)
  • Hypersensitivity reactions
  • Hydroxychloroquine and Chloroquine can diminish therapeutic effect of remdesivir
  • Amiodarone: enhance hepatotoxic effects of remdesivir
  • CYP3A4 inducers (strong) may decrease remdesivir concentration

Mechanism of action: inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase

Average half-life: 1 hour

Risk of reduced antiviral activity when co-administered with chloroquine or hydroxychloroquine